Cetera Investment Advisers raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 41.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,207 shares of the biopharmaceutical company’s stock after purchasing an additional 3,288 shares during the period. Cetera Investment Advisers’ holdings in Gilead Sciences were worth $792,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Keel Point LLC increased its holdings in shares of Gilead Sciences by 0.4% in the 2nd quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after acquiring an additional 12 shares during the last quarter. West Oak Capital LLC increased its holdings in shares of Gilead Sciences by 0.7% in the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after acquiring an additional 32 shares during the last quarter. First Heartland Consultants Inc. increased its holdings in shares of Gilead Sciences by 0.4% in the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock valued at $632,000 after acquiring an additional 39 shares during the last quarter. Princeton Portfolio Strategies Group LLC increased its holdings in shares of Gilead Sciences by 0.4% in the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after acquiring an additional 41 shares during the last quarter. Finally, Arrow Financial Corp increased its holdings in shares of Gilead Sciences by 0.3% in the 2nd quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock valued at $1,258,000 after acquiring an additional 45 shares during the last quarter. 76.23% of the stock is currently owned by institutional investors.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $76.58 on Thursday. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The firm has a market capitalization of $99,119.69, a price-to-earnings ratio of 7.92, a PEG ratio of -1.27 and a beta of 1.13. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company’s revenue was down 13.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.75 earnings per share. analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be issued a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.72%. Gilead Sciences’s dividend payout ratio (DPR) is 23.69%.
A number of equities research analysts have recently weighed in on the company. BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a report on Thursday. Leerink Swann boosted their price target on Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a report on Thursday, October 19th. Berenberg Bank reiterated a “buy” rating and issued a $86.00 price target (up from $79.00) on shares of Gilead Sciences in a report on Sunday, August 20th. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Finally, Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a report on Thursday, October 19th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $85.11.
In other news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the sale, the executive vice president now owns 77,363 shares in the company, valued at $5,788,299.66. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $82.65, for a total value of $2,066,250.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 494,999 shares of company stock valued at $37,404,139. Insiders own 1.30% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Gilead Sciences, Inc. (GILD) Holdings Boosted by Cetera Investment Advisers” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/14/gilead-sciences-inc-gild-holdings-boosted-by-cetera-investment-advisers.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.